Pancreatic Cancer Research

ResearcherSir Run Run Shaw HospitalActive in the last 2 years

Liangjing Zhou

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5110327014. Sources: OpenAlex.

Their work

Papers
14 (first author 5, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
20
Papers, trials and grants by year

2014: 1 paper · 2015: 2 papers · 2016: none · 2017: 2 papers · 2018: 4 papers · 2019: 2 papers · 2020: none · 2021: none · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 14

  1. Filgotinib inhibits METTL3-mediated m6A of EIF3A by targeting ERG-TBP to suppress PDAC progression JAK-STAT3-independently. Co-author DOI 10.1038/s41698-026-01396-z↗
  2. Discovery of an 8-oxoguanine regulator PCBP1 inhibitor by virtual screening and its synergistic effects with ROS-modulating agents in pancreatic cancer. Co-author DOI 10.3389/fmolb.2024.1441550↗
  3. ZC3H13-mediated N6-methyladenosine modification of PHF10 is impaired by fisetin which inhibits the DNA damage response in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2022.01.013↗
  4. The distinct role of CD73 in the progression of pancreatic cancer. Co-author DOI 10.1007/s00109-018-01742-0↗
  5. Down-regulation of miR-30a-5p is Associated with Poor Prognosis and Promotes Chemoresistance of Gemcitabine in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.7150/jca.31191↗
  6. Interferon Gamma Inhibits CXCL8-Induced Proliferation and Migration of Pancreatic Cancer BxPC-3 Cell Line via a RhoGDI2/Rac1/NF-κB Signaling Pathway. Co-author DOI 10.1089/jir.2018.0070↗
  7. IFN-γ induces the upregulation of RFXAP via inhibition of miR-212-3p in pancreatic cancer cells: A novel mechanism for IFN-γ response. First author DOI 10.3892/ol.2018.7777↗
  8. Down-expression of CD36 in pancreatic adenocarcinoma and its correlation with clinicopathological features and prognosis. First author DOI 10.7150/jca.21046↗
  9. High Expression of P38α and Preoperative Carbohydrate Antigen 19-9 Indicate Poor Prognosis in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.7150/jca.21683↗
  10. Prognostic value of programmed cell death protein 1 expression on CD8+ T lymphocytes in pancreatic cancer. First author DOI 10.1038/s41598-017-08479-9↗
  11. Overexpressions of miR-212 are associated with poor prognosis of patients with pancreatic ductal adenocarcinoma. First author DOI 10.3233/cbm-160671↗
  12. Overexpressions of DLL4 and CD105 are Associated with Poor Prognosis of Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s12253-015-9937-4↗
  13. Pancreatic cancer-derived exosomes transfer miRNAs to dendritic cells and inhibit RFXAP expression via miR-212-3p. First author DOI 10.18632/oncotarget.4924↗
  14. Pancreatic cancer derived exosomes regulate the expression of TLR4 in dendritic cells via miR-203. Co-author DOI 10.1016/j.cellimm.2014.09.004↗

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Guoping Ding · 11 shared papers, 2014–2022 · strength 1.00
  2. Liping Cao · 8 shared papers, 2017–2024 · strength 0.91
  3. Shengnan Jia · 7 shared papers, 2017–2022 · strength 0.70
  4. Chaolei Zhang · 3 shared papers, 2022–2026 · strength 0.67
  5. Kexiong Qiao · 2 shared papers, 2024–2026 · strength 0.52
  6. Shengnan Jia · 2 shared papers, 2024–2026 · strength 0.52
  7. Liping Cao · 5 shared papers, 2014–2018 · strength 0.38
  8. Xiaofan Pu · 1 shared paper, 2026 · strength 0.30
  9. Mingjie Zhang · 3 shared papers, 2018–2019 · strength 0.29
  10. Zhengrong Wu · 3 shared papers, 2015–2019 · strength 0.25
  11. Weihua Yu · 2 shared papers, 2019 · strength 0.20
  12. Tao Shen · 2 shared papers, 2017–2018 · strength 0.19
  13. Jionghuang Chen · 3 shared papers, 2014–2018 · strength 0.18
  14. Chaojie Huang · 1 shared paper, 2022 · strength 0.15
  15. Tianshu Pang · 1 shared paper, 2022 · strength 0.15
  16. Guixing Jiang · 2 shared papers, 2015–2018 · strength 0.13
  17. Zhengrong Wu · 1 shared paper, 2017 · strength 0.10
  18. Xiaodong Xu · 1 shared paper, 2018 · strength 0.09
  19. Ting Zhao · 1 shared paper, 2018 · strength 0.09
  20. Min Zhou · 1 shared paper, 2014 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.